Sentinel Node Biopsy Market: as CMS grants transitional pass-through reimbursement to magnetic tracer technology and the underlying radioisotope supply chain remains exposed to recurring Technetium-99 shortages, non-radioactive tracer platforms are converting a persistent nuclear medicine supply vulnerability into a genuine reimbursement-backed alternative, so tracer technology selection is increasingly a supply chain resilience decision as much as a clinical performance one.

The global sentinel node biopsy market size was USD 0.84 Billion in 2025 and is expected to register a revenue CAGR of 6.8% during the forecast period.Market revenue growth is driven by factors such as rising early-stage breast and melanoma cancer incidence, fluorescence imaging-guided sentinel node biopsy adoption replacing radioisotope mapping, and expanding gynaecological cancer staging indications.The first driving factor is rising early-stage breast and melanoma cancer incidence, sustaining structural demand for sentinel node biopsy as the standard-of-care staging procedure across surgical oncology programmes globally.The second driving factor is fluorescence imaging-guided sentinel node biopsy adoption replacing conventional radioisotope mapping, driven both by comparable clinical detection accuracy and by growing exposure to radioisotope supply chain disruption.The third driving factor is expanding gynaecological cancer staging indications, extending sentinel node biopsy technique beyond its original breast and melanoma applications into cervical and endometrial cancer surgical staging protocols.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a non-radioactive tracer technology's reimbursement approval widens its addressable hospital adoption every time a radioisotope supply disruption forces a surgical oncology programme to seek an alternative, converting an intermittent nuclear medicine supply vulnerability into durable demand for tracer technologies that do not depend on that supply chain at all.Once a magnetic or fluorescence tracer technology secures reimbursement coverage comparable to conventional radioisotope tracers, every hospital surgical oncology programme that has experienced a Technetium-99 shortage-driven surgery delay gains a viable, already-reimbursed alternative it can adopt permanently rather than only during the acute shortage period, so non-radioactive tracer adoption compounds with each successive radioisotope supply disruption rather than reverting once any single shortage resolves.As a result, demand and revenue share are concentrating around non-radioactive tracer manufacturers with established reimbursement pathways, that hold the deepest clinical evidence supporting detection rates comparable to radioisotope tracers, and the forecast tilts toward these reimbursement-backed alternative tracer platforms rather than manufacturers still dependent exclusively on the conventional radioisotope supply chain.For instance, effective January 1, 2025, CMS granted transitional pass-through payment status to Hologic/Endomagnetics' Magtrace magnetic lymphatic tracer, making hospital outpatient departments and ambulatory surgical centres eligible for separate Medicare reimbursement precisely as US breast cancer surgery programmes faced recurring Technetium-99 shortages that were actively delaying patient procedures.These are some of the key factors driving revenue growth of the market.

Because Technetium-99m supply depends on a limited number of global nuclear reactor sources, periodic radioisotope shortages can delay scheduled sentinel node biopsy procedures at hospitals still reliant exclusively on conventional radioisotope tracer technique.

Skin discoloration and imaging artifact side effects are a second constraint specific to magnetic tracer alternatives, as injected magnetic particles can cause visible skin discoloration at the injection site and create artifacts on subsequent MRI imaging that complicate post-treatment surveillance.

Reimbursement policy transition uncertainty is a third constraint, as transitional pass-through payment structures for newer, non-radioactive tracer technologies are time-limited, creating the same kind of interim reimbursement uncertainty that has historically constrained adoption of novel device-based technologies pending permanent coverage determination.

These factors substantially limit sentinel node biopsy market growth over the forecast period.

The clearest driver of demand is the alignment between reimbursement policy timing and an active clinical supply chain crisis, converting a routine coverage decision into an urgently needed alternative for hospitals facing delayed patient procedures. A non-radioactive tracer technology only captures durable, lasting hospital adoption if reimbursement makes it economically viable for routine, not just emergency, use, and CMS granting Magtrace transitional pass-through payment status effective January 1, 2025 gave hospital outpatient departments and ambulatory surgical centres exactly that separate Medicare reimbursement eligibility. The timing was clinically consequential: in the month preceding the reimbursement decision, breast cancer patients across the US had experienced surgery delays specifically due to ongoing Technetium-99 shortages, according to clinical accounts from UCSF surgical oncology faculty. Because Magtrace removes reliance on Nuclear Medicine departments entirely, operating departments gained the ability to schedule sentinel node biopsy procedures without first coordinating radioisotope tracer availability, unlocking more flexible surgical scheduling including delayed sentinel node biopsy technique. The effect on the market is that hospitals adopting magnetic tracer technology during the acute 2025 shortage period are likely to retain that technology permanently as a hedge against future radioisotope supply disruption, rather than reverting to exclusive radioisotope dependence once any single shortage resolves. These are some of the key factors driving revenue growth of the market.

The second driver is the extension of fluorescence-guided sentinel node mapping technique validated in breast cancer and melanoma into new oncological indications where the technique had not previously been standard practice. A fluorescence imaging technique only expands into new cancer type indications if the underlying clinical evidence demonstrates detection rates that match established radioisotope-based technique, and multiple 2025 published clinical evidence reviews have documented indocyanine green fluorescence achieving detection accuracy comparable to Technetium-99m-based lymphoscintigraphy across breast cancer and melanoma applications specifically. Endomagnetics separately achieved EU Medical Device Regulation certification for its Magseed marker in January 2026, reflecting continued regulatory investment in the broader non-radioactive localization and mapping technology category beyond the core Magtrace tracer product. Clinical evidence published throughout 2025 comparing indocyanine green fluorescence to Technetium-99m in breast cancer sentinel node biopsy, including a Romanian institutional study of 476 patients, continues to build the comparative evidence base supporting fluorescence technique adoption in routine, non-research clinical practice. The effect on the market is that fluorescence and hybrid tracer technology is capturing an increasing share of sentinel node biopsy procedure volume as the clinical evidence base extends validated technique into gynaecological and other cancer types beyond the original breast and melanoma applications. These are some of the key factors driving revenue growth of the market.

“CMS's transitional pass-through reimbursement for Magtrace magnetic lymphatic tracer took effect January 1, 2025, precisely as breast cancer patients across the United States were experiencing surgery delays due to ongoing Technetium-99 shortages, converting a routine coverage decision into an urgently needed supply chain resilience solution.”

However, the sentinel node biopsy market faces severe adoption constraints from radioisotope supply chain vulnerability, skin discoloration and imaging artifact side effects with magnetic tracers, and reimbursement policy transition uncertainty.

Because Technetium-99m supply depends on a limited number of global nuclear reactor sources, periodic radioisotope shortages continue to create scheduling risk for hospitals still reliant exclusively on conventional radioisotope tracer technique, even as alternative technologies gain reimbursement support.

Skin discoloration and imaging artifact side effects specific to magnetic tracer alternatives compound this, as injected magnetic particles can cause visible skin discoloration at the injection site, a side effect actively being studied through a formal post-approval surveillance study, and can create artifacts on subsequent MRI imaging that complicate post-treatment surveillance for certain patients.

Reimbursement policy transition uncertainty is the third constraint, as transitional pass-through payment structures for newer, non-radioactive tracer technologies are time-limited by design, creating the same kind of interim reimbursement uncertainty that has historically constrained novel device technology adoption pending a permanent, durable coverage determination.

These factors substantially limit sentinel node biopsy market growth over the forecast period.

Based on product type, the global sentinel node biopsy market is segmented into radioisotope tracers, blue dye tracers, fluorescence/NIR imaging systems, and hybrid tracer systems. Radioisotope tracers hold the largest revenue share, because Technetium-99m-based lymphoscintigraphy remains the established clinical standard across the majority of global sentinel node biopsy procedures despite growing non-radioactive alternative adoption. Fluorescence/NIR imaging systems are expected to register the fastest revenue growth rate over the forecast period, driven by expanding clinical evidence supporting comparable detection accuracy and reduced dependence on the radioisotope supply chain.

Based on cancer type, the global sentinel node biopsy market is segmented into breast cancer, melanoma/skin cancer, gynaecological cancers, colorectal cancer, and gastric/other GI cancers. Breast cancer holds the largest cancer-type revenue share, reflecting the procedure's origin and continued predominant use as the standard-of-care axillary staging approach for early-stage breast cancer. Gynaecological cancers are expected to register the fastest revenue growth rate, driven by expanding cervical and endometrial cancer surgical staging protocol adoption of sentinel node biopsy technique validated originally in breast cancer and melanoma.

Based on regional analysis, the sentinel node biopsy market in North America accounted for largest revenue share in 2025. The United States leads because CMS reimbursement policy directly shapes tracer technology adoption nationally, and because the country hosts the headquarters of Hologic/Endomagnetics' US operations and the largest concentration of academic surgical oncology programmes. The 2025 Technetium-99 shortage that directly affected US breast cancer surgery scheduling, combined with the concurrent CMS Magtrace reimbursement decision, reflects the concentration of both radioisotope supply chain risk and reimbursement policy influence at the US national level. The concentration of leading tracer and imaging technology manufacturers in the United States also means new non-radioactive tracer technologies are often cleared and reimbursed domestically before international market expansion.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and the Netherlands represent the four largest national markets, with established national health service sentinel node biopsy reimbursement frameworks. Endomagnetics' EU Medical Device Regulation certification for its Magseed marker, achieved in January 2026, reflects continued European regulatory investment in the non-radioactive localization technology category. The result is steady rather than rapid growth, shaped more by national procurement and reimbursement cycle timing than by underlying clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period, driven by China, Japan, and India's expanding surgical oncology infrastructure and rising breast cancer diagnosis rates. China's rapidly expanding hospital oncology network and Japan's established surgical oncology training programmes are the region's two largest growth contributors. This leaves more room for growth than in the more mature North American and European sentinel node biopsy markets, where manufacturer-institution relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with sentinel node biopsy programme access concentrated at academic cancer centres in São Paulo and Mexico City. Iran-US sanctions continue to disrupt freight and import costs for the specialised radioisotope generator, fluorescence dye, and magnetic tracer materials that Latin American surgical oncology programmes depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed material costs and slowing tracer distribution beyond the region's main academic cancer centres through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare investment programme driving new surgical oncology infrastructure development. The UAE is the most established market on the continent for sentinel node biopsy procedure capability, while the Gulf states more broadly are still building specialist surgical oncology infrastructure largely from scratch.